Advanced Biomedical (ABMT) 10-Q 23 Jun 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Apr. 30, 2014	Jun. 23, 2014
StockIssuedForServices	'	'
Entity Registrant Name	'Advanced Biomedical Technologies Inc.	'
Entity Central Index Key	'0001385799	'
Document Type	'10-Q	'
Document Period End Date	30-Apr-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--10-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	56,874,850
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Apr. 30, 2014	Oct. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$56,994	$48,380
Other receivables and prepaid expenses	22,722	21,105
Total Current Assets	79,716	69,485
PROPERTY AND EQUIPMENT, NET	118,149	126,568
DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT	293	1,140
TOTAL ASSETS	198,158	197,193
CURRENT LIABILITIES	'	'
Other payables and accrued expenses	55,608	59,237
Due to directors	416,693	455,574
Due to a stockholder	400,929	349,911
Due to related parties	2,554,946	2,266,916
Total Current Liabilities	3,428,176	3,131,638
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' DEFICIT	'	'
Common stock, $0.00001 par value, 100,000,000 shares authorized, 56,874,850 shares issued and outstanding as of April 30, 2014 and October 31, 2013	569	569
Additional paid-in capital	1,918,333	1,907,889
Accumulated deficit during development stage	-4,956,415	-4,572,351
Accumulated other comprehensive loss	-192,505	-270,552
Total Stockholders' Deficit	-3,230,018	-2,934,445
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$198,158	$197,193

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Apr. 30, 2014	Oct. 31, 2013
Condensed Consolidated Balance Sheets Parenthetical	'	'
Common Stock Shares Par Value	$0.00	$0.00
Common Stock Shares Authorized	100,000,000	100,000,000
Common Stock Shares Issued	56,874,850	56,874,850
Common Stock Shares Outstanding	56,874,850	56,874,850

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended		139 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
OPERATING EXPENSES	'	'	'	'	'
General and administrative expenses	$117,885	$87,971	$251,064	$197,082	$4,000,563
Depreciation	6,662	6,490	13,360	12,928	330,195
Research and development	9,418	3,375	19,834	22,786	307,266
Total Operating Expenses	133,965	97,836	284,258	232,796	4,638,024
LOSS FROM OPERATIONS	-133,965	-97,836	-284,258	-232,796	-4,638,024
OTHER EXPENSES	'	'	'	'	'
Government grants	'	'	'	'	244,479
Interest income	39	15	63	35	1,946
Interest paid to a stockholder and related parties	-43,654	-32,926	-85,071	-63,710	-479,609
Imputed interest	-5,091	-5,801	-10,444	-11,766	-262,871
Others, net	-2,093	-2,018	-4,354	-5,590	-39,541
Total Other Expenses, net	-50,799	-40,730	-99,806	-81,031	-535,596
NET LOSS	-184,764	-138,566	-384,064	-313,827	-5,173,620
Net loss attributable to non-controlling interests	'	'	'	'	217,205
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	-184,764	-138,566	-384,064	-313,827	-4,956,415
OTHER COMPREHENSIVE INCOME (LOSS)	'	'	'	'	'
Foreign currency translation gain (loss)	94,032	-20,226	78,047	-26,682	-192,505
COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	($90,732)	($158,792)	($306,017)	($340,509)	($5,148,920)
Net loss per share-basic and diluted	$0	$0	($0.01)	($0.01)	'
Weighted average number of shares outstanding during the period - basic and diluted	56,874,850	56,574,850	56,874,850	56,574,850	'

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (UNAUDITED) (USD $)	Common Stock	Shares to be issued	Stock subscription receivable	Additional Paid-In Capital	Deferred stock compensation	Accumulated deficit during developmental stage	Accumulated Other Comprehensive Loss	Non-controlling Interest	Total
Beginning Balance, Amount at Dec. 31, 2002	'	'	'	'	'	'	'	'	'
Stock issued to founders for cash, Shares	50,510,000	'	'	'	'	'	'	'	'
Stock issued to founders for cash, Amount	$505	'	'	$275,002	'	'	'	$217,205	$492,712
Net loss	'	'	'	'	'	-40,343	'	-17,290	-57,633
Foreign currency translation gain (loss)	'	'	'	'	'	'	-225	10	-215
Ending Balance, Amount at Dec. 31, 2003	505	'	'	275,002	'	-40,343	-225	199,925	434,864
Ending Balance, Shares at Dec. 31, 2003	50,510,000	'	'	'	'	'	'	'	'
Net loss	'	'	'	'	'	-65,960	'	-28,269	-94,229
Foreign currency translation gain (loss)	'	'	'	'	'	'	-357	2	-355
Ending Balance, Amount at Dec. 31, 2004	505	'	'	275,002	'	-106,303	-582	171,658	340,280
Ending Balance, Shares at Dec. 31, 2004	50,510,000	'	'	'	'	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	23,103	'	'	'	'	23,103
Net loss	'	'	'	'	'	-357,863	'	-153,370	-511,233
Foreign currency translation gain (loss)	'	'	'	'	'	'	-12,290	2,064	-10,226
Ending Balance, Amount at Dec. 31, 2005	505	'	'	298,105	'	-464,166	-12,872	20,352	-158,076
Ending Balance, Shares at Dec. 31, 2005	50,510,000	'	'	'	'	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	27,184	'	'	'	'	27,184
Net loss	'	'	'	'	'	-172,738	'	-18,276	-191,014
Foreign currency translation gain (loss)	'	'	'	'	'	'	-6,084	-2,076	-8,160
Ending Balance, Amount at Dec. 31, 2006	505	'	'	325,289	'	-636,904	-18,956	'	-330,066
Ending Balance, Shares at Dec. 31, 2006	50,510,000	'	'	'	'	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	39,021	'	'	'	'	39,021
Net loss	'	'	'	'	'	-196,871	'	'	-196,871
Foreign currency translation gain (loss)	'	'	'	'	'	'	-27,401	'	-27,401
Ending Balance, Amount at Dec. 31, 2007	505	'	'	364,310	'	-833,775	-46,357	'	-515,317
Ending Balance, Shares at Dec. 31, 2007	50,510,000	'	'	'	'	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	27,764	'	'	'	'	27,764
Net loss	'	'	'	'	'	-227,038	'	'	-227,038
Foreign currency translation gain (loss)	'	'	'	'	'	'	-35,833	'	-35,833
Ending Balance, Amount at Oct. 31, 2008	505	'	'	392,074	'	-1,060,813	-82,190	'	-750,424
Beginning Balance, Shares at Oct. 31, 2008	50,510,000	'	'	'	'	'	'	'	'
Distributed to the stockholders	'	'	'	-31,409	'	'	'	'	-31,409
Contributed capital	'	'	'	26,950	'	'	'	'	26,950
Stock issued for cash in private placement ($1.15 per share) , Shares	7,000	'	'	'	'	'	'	'	'
Stock issued for cash in private placement ($1.15 per share), Amount	'	'	'	8,050	'	'	'	'	8,050
Stock issued for services ($3.05 per share), Shares	100,000	'	'	'	'	'	'	'	'
Stock issued for services ($3.05 per share), Amount	1	'	'	304,999	-292,292	'	'	'	12,708
Recapitalization, Shares	5,104,000	'	'	'	'	'	'	'	'
Recapitalization, Amount	51	'	'	-51	'	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	31,656	'	'	'	'	31,656
Net loss	'	'	'	'	'	-558,432	'	'	-558,432
Foreign currency translation gain (loss)	'	'	'	'	'	'	-1,856	'	-1,856
Ending Balance, Amount at Oct. 31, 2009	557	'	'	732,269	-292,292	-1,619,245	-84,046	'	-1,262,757
Ending Balance, Shares at Oct. 31, 2009	55,721,000	'	'	'	'	'	'	'	'
Amortisation for stock issued for services	'	'	'	'	349,516	'	'	'	349,516
Stock to be issued for cash in private placement ($1.0 per share), Amount	'	2	-230,000	229,998	'	'	'	'	'
Stock issued for cash in private placement ($1.5 per share) , Shares	160,167	'	'	'	'	'	'	'	'
Stock issued for cash in private placement ($1.5 per share), Amount	2	'	'	240,248	'	'	'	'	240,250
Stock issued for services ($1 per share), Shares	263,683	'	'	'	'	'	'	'	'
Stock issued for services ($1 per share), Amount	'	'	'	263,680	-263,683	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	28,356	'	'	'	'	28,356
Net loss	'	'	'	'	'	-816,799	'	'	-816,799
Foreign currency translation gain (loss)	'	'	'	'	'	'	-29,063	'	-29,063
Ending Balance, Amount at Oct. 31, 2010	562	2	-230,000	1,494,551	-206,459	-2,436,044	-113,109	'	-1,490,497
Ending Balance, Shares at Oct. 31, 2010	56,144,850	'	'	'	'	'	'	'	'
Amortisation for stock issued for services	'	'	'	'	223,958	'	'	'	223,958
Stock to be issued for cash in private placement ($1.0 per share), Shares	230,000	'	'	'	'	'	'	'	'
Stock to be issued for cash in private placement ($1.0 per share), Amount	2	-2	-230,000	-2	230,000	'	'	'	230,000
Stock issued for cash in private placement ($1 per share), Shares	100,000	'	'	'	'	'	'	'	'
Stock issued for cash in private placement ($1 per share), Amount	1	'	'	104,999	-105,000	'	'	'	'
Imputed interest on advances from a stockholder and related company	'	'	'	27,060	'	'	'	'	27,060
Net loss	'	'	'	'	'	-487,439	'	'	-487,439
Foreign currency translation gain (loss)	'	'	'	'	'	'	-65,852	'	-65,852
Ending Balance, Amount at Oct. 31, 2011	565	'	'	1,626,610	-87,501	-2,923,483	-178,961	'	-1,562,770
Ending Balance, Shares at Oct. 31, 2011	56,474,850	'	'	'	'	'	'	'	'
Amortisation for stock issued for services	'	'	'	'	105,834	'	'	'	105,834
Stock issued for services ($0.2 per share), Shares	100,000	'	'	'	'	'	'	'	'
Stock issued for services ($0.2 per share), Amount	1	'	'	19,999	-20,000	'	'	'	'
Imputed interest on advances from directors	'	'	'	25,347	'	'	'	'	25,347
Net loss	'	'	'	'	'	-758,525	'	'	-758,525
Foreign currency translation gain (loss)	'	'	'	'	'	'	-36,081	'	-36,081
Ending Balance, Amount at Oct. 31, 2012	566	'	'	1,671,956	-1,667	-3,682,008	-215,042	'	-2,226,195
Ending Balance, Shares at Oct. 31, 2012	56,574,850	'	'	'	'	'	'	'	'
Amortisation for stock issued for services	'	'	'	'	1,667	'	'	'	1,667
Imputed interest on advances from directors	'	'	'	22,936	'	'	'	'	22,936
Stock issued for services ($0.71 per share), Shares	300,000	'	'	'	'	'	'	'	'
Stock issued for services ($0.71 per share), Amount	3	'	'	212,997	'	'	'	'	213,000
Net loss	'	'	'	'	'	-890,343	'	'	-890,343
Foreign currency translation gain (loss)	'	'	'	'	'	'	-55,510	'	-55,510
Ending Balance, Amount at Oct. 31, 2013	569	'	'	1,907,889	'	-4,572,351	-270,552	'	-2,934,445
Ending Balance, Shares at Oct. 31, 2013	56,874,850	'	'	'	'	'	'	'	'
Imputed interest on advances from directors	'	'	'	10,444	'	'	'	'	10,444
Net loss	'	'	'	'	'	-384,064	'	'	-384,064
Foreign currency translation gain (loss)	'	'	'	'	'	'	78,047	'	78,047
Ending Balance, Amount at Apr. 30, 2014	$569	'	'	$1,918,333	'	($4,956,415)	($192,505)	'	($3,230,018)
Ending Balance, Shares at Apr. 30, 2014	56,874,850	'	'	'	'	'	'	'	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended		139 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net loss	($384,064)	($313,827)	($4,956,415)
Adjustments to reconcile net loss to cash used in operating activities:	'	'	'
Depreciation	13,360	12,928	330,195
Loss on disposal of property and equipment	'	'	11,704
Stock issued for services	'	1,667	906,683
Non-controlling interests	'	'	-217,205
Imputed interest	10,444	11,766	262,871
Changes in operating assets and liabilities	'	'	'
Increase (decrease) in Other receivables and prepaid expenses	-2,208	7	-22,722
(Decrease) increase in Other payables and accrued expenses	-2,570	-20,053	55,608
Net cash used in operating activities	-365,038	-307,512	-3,629,281
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of property and equipment	-8,087	-1,525	-460,048
Decrease (increase) in deposit for purchase of property and equipment	836	'	-293
Net cash used in investing activities	-7,251	-1,525	-460,341
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Stock issued to founders	'	'	505
Proceeds from issuance of shares	'	'	478,300
Contribution by stockholders	'	'	519,157
Distributed to stockholders	'	'	-31,409
Due to a stockholder	51,010	47,677	400,929
Due to directors	-28,051	-32,112	416,693
Due to related parties	359,099	275,947	2,554,946
Net cash provided by financing activities	382,058	291,512	4,339,121
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	-1,155	179	-192,505
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	8,614	-17,346	56,994
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	48,380	49,092	'
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$56,994	$31,746	$56,994

1_BASIS_OF_PRESENTATION

1. BASIS OF PRESENTATION	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
1. BASIS OF PRESENTATION	'
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
	In the opinion of management, the unaudited condensed consolidated financial statements contain adjustments considered necessary to present fairly the Company's financial position as of April 30, 2014, the consolidated results of operations for the three and six months ended April 30, 2014 and 2013 and for the period from September 25, 2002 (inception) to April 30, 2014 and consolidated statements of cash flows for the six months ended  April 30, 2014 and 2013 and for the period from September 25, 2002 (inception) to April 30, 2014 on an accrual basis and in accordance with accounting principles generally accepted in the United States of America for interim financial information and rules and regulations of the SEC. The consolidated results for the three and six months ended April 30, 2014 are not necessarily indicative of the results to be expected for the entire fiscal year ending October 31, 2014. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2013 appearing in the Company's annual report on Form 10-K as filed with the Securities and Exchange Commission on February 13,  2014.
	The reporting currency of the Company is US dollar.

2_ORGANIZATION

2. ORGANIZATION	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
2. ORGANIZATION	'
	Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT” or the “Company”) was incorporated in Nevada on September 12, 2006.
	Shenzhen Changhua Biomedical Engineering Company Limited (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, fka “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities” (formerly Statement of Financial Accounting Standard (“SFAS”) No. 7, “Accounting and Reporting by Development Stage Enterprise”), is considered a Development Stage Company.
	Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company and was then owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder at the time and 37% by a third party corporation.
	On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua were under common control and management, the acquisition was accounted for as a reorganization of entities under common control.
	Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.
	On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which ABMT issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.
	Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.
	On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.
	On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.
	The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.
	Accordingly, these financial statements include the following:
	(1)	The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.
	(2)	The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

3_PRINCIPLES_OF_CONSOLIDATION

3. PRINCIPLES OF CONSOLIDATION	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
3. PRINCIPLES OF CONSOLIDATION	'
	The accompanying condensed consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The non-controlling interests in periods prior to 2012 represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.
	All significant inter-company balances and transactions have been eliminated in consolidation.

4_USE_OF_ESTIMATES

4. USE OF ESTIMATES	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
4. USE OF ESTIMATES	'
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

5_RELATED_PARTY_TRANSACTIONS

5. RELATED PARTY TRANSACTIONS	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
5. RELATED PARTY TRANSACTIONS	'
	As of April 30, 2014 and October 31, 2013, the Company owed a stockholder $400,929 and $349,911 respectively, which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.
	As of April 30, 2014 and October 31, 2013, the Company owed two related parties a total of $2,554,946 and $2,266,916 respectively, which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amounts owed.
	Total interest expenses on advances from a stockholder and the related parties accrued for the three and six months ended April 30, 2014 and 2013 and for the period from September 25, 2002 (inception) through April 30, 2014 were $43,654, $32,926, $85,071, $63,710 and $479,609 respectively.
	As of April 30, 2014 and October 31, 2013, the Company owed $416,693 and $455,574 respectively, to two directors for advances made on an unsecured basis, repayable on demand and interest free.
	Imputed interest charged at 5% per annum on the amounts owed to two directors is $5,091, $5,801, $10,444, $11,766 and $262,871 for the three and six months ended April 30, 2014 and 2013 and for the period from September 25, 2002 (inception) through April 30, 2014 respectively.

6_STOCKHOLDERS_EQUITY

6. STOCKHOLDERS EQUITY	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
6. STOCKHOLDERS EQUITY	'
	Common stock
	For the three and six months ended April 30, 2014 and 2013 and for the period from September 25, 2002 (inception) through April 30, 2014, the Company recognized $0, $0, $0, $1,667 and $906,683 respectively as consultancy fees included in general and administrative expenses and recorded deferred stock compensation carried forward of $0 as of April 30, 2014 and October 31, 2013 for these services.

7_COMMITMENTS_AND_CONTINGENCIE

7. COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
7. COMMITMENTS AND CONTINGENCIES	'
	The Company’s existing rental leases do not contain significant restrictive provisions.  The following is a schedule by year of future minimum lease obligations under non-cancelable rental operating leases which fall due as follows:
	Fiscal years ending October 31,
	2014	$	11,841
	2015		1,516
	Total	$	13,357

8_FAIR_VALUE_OF_FINANCIAL_INST

8. FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Apr. 30, 2014
Fair Value Disclosures [Abstract]	'
8. FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	The Financial Accounting Standards Board (FASB) Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued liabilities and due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

9_RECENT_ACCOUNTING_PRONOUNCEM

9. RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
9. RECENT ACCOUNTING PRONOUNCEMENTS	'
	On June 10, 2014, FASB issued a new accounting standard that reduces some of the disclosure and reporting requirements for development stage entities. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. As of such date, among other things, development stage entities will no longer be required to report inception-to-date information. The Company is currently assessing what effects this will have on the presentation of its financial statements in future filings.

10_GOING_CONCERN

10. GOING CONCERN	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
10. GOING CONCERN	'
	As reflected in the accompanying unaudited condensed consolidated financial statements, the Company has not commenced revenue producing operations and has an accumulated deficit of $4,956,415 as of April 30, 2014 that includes a net loss of $384,064 for the six months ended April 30, 2014. As of April 30, 2014, the Company’s total current liabilities exceeded its total current assets by $3,348,460 and the Company used cash in operations of $365,038 for the six months ended on that date. These factors raise substantial doubt about its ability to continue as a going concern.  In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying condensed consolidated balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
	Management has taken the following steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern.  The Company is actively pursuing additional funding and strategic partners, which will enable the Company to implement its business plan.  Management believes that these actions as successful will allow the Company to continue its operations through the next fiscal year.

11_SUBSEQUENT_EVENT

11. SUBSEQUENT EVENT	6 Months Ended
	Apr. 30, 2014
Subsequent Events [Abstract]	'
11. SUBSEQUENT EVENT	'
	In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent from April 30, 2014 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements, other than stated below:
	On May 13, 2014, the Company received cash advance from Tie Jun Chen amounted to RMB300,000 (equivalent to approximately $48,000).

1_SUMMARY_OF_SIGNIFICANT_ACCOU

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	6 Months Ended
	Apr. 30, 2014
Notes to Financial Statements	'
Organization	'
	Advanced BioMedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT” or the “Company”) was incorporated in Nevada on September 12, 2006.
	Shenzhen Changhua Biomedical Engineering Company Limited (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the China Food and Drug Administration (“CFDA”, fka “SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities” (formerly Statement of Financial Accounting Standard (“SFAS”) No. 7, “Accounting and Reporting by Development Stage Enterprise”), is considered a Development Stage Company.
	Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on May 31, 2007 as an investment holding company and was then owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder at the time and 37% by a third party corporation.
	On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua were under common control and management, the acquisition was accounted for as a reorganization of entities under common control.
	Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.
	On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which ABMT issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.
	Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.
	On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became a 80.7% stockholder of ABMT.
	On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.
	The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.
	Accordingly, these financial statements include the following:
	(1)	The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.
	(2)	The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.
Principles of consolidation	'
	The accompanying condensed consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The non-controlling interests in periods prior to 2012 represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.
	All significant inter-company balances and transactions have been eliminated in consolidation.
Use of estimates	'
	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements	'
	On June 10, 2014, FASB issued a new accounting standard that reduces some of the disclosure and reporting requirements for development stage entities. The change will be effective for interim and annual reporting periods beginning after December 15, 2014, with early adoption permitted. As of such date, among other things, development stage entities will no longer be required to report inception-to-date information. The Company is currently assessing what effects this will have on the presentation of its financial statements in future filings.

7_COMMITMENTS_AND_CONTINGENCIE1

7. COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Apr. 30, 2014
Commitments And Contingencies Tables	'
Operating lease outstanding commitments	'
	Fiscal years ending October 31,
	2014		11,841
	2015		1,516
	Total	$	13,357

5_RELATED_PARTY_TRANSACTIONS_D

5. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		139 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2014	Oct. 31, 2013	Apr. 30, 2014	Oct. 31, 2013	Apr. 30, 2014	Oct. 31, 2013
						Stockholder	Stockholder	Two Related Parties	Two Related Parties	Two Directors	Two Directors
Unsecured debt owed to a stockholder	'	'	'	'	'	$400,929	$349,911	'	'	'	'
Related party debt	'	'	'	'	'	'	'	2,554,946	2,266,916	416,693	455,574
Imputed interest on advances from two directors	5,091	5,801	10,444	11,766	262,871	'	'	'	'	'	'
Interest expenses on advances from stockholder and related parties	$43,654	$32,926	$85,071	$63,710	$479,609	'	'	'	'	'	'

6_STOCKHOLDERS_EQUITY_Details_

6. STOCKHOLDERS EQUITY (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		139 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Oct. 31, 2013
Stockholders Equity Details Narrative	'	'	'	'	'	'
Consultancy fees	$0	$0	$0	$1,667	$906,683	'
Deferred stock compensation carried forward	$0	'	$0	'	$0	$0

7_COMMITMENTS_AND_CONTINGENCIE2

7. COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Apr. 30, 2014
Commitments And Contingencies Details	'
2014	$11,841
2015	1,516
Total	$13,357

10_GOING_CONCERN_Details_Narra

10. GOING CONCERN (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		139 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Oct. 31, 2013
Going Concern Details Narrative	'	'	'	'	'	'
Accumulated deficit	$4,956,415	'	$4,956,415	'	$4,956,415	$4,572,351
Net loss	-184,764	-138,566	-384,064	-313,827	-5,173,620	'
Current liabilities exceeding current assets	3,348,460	'	3,348,460	'	3,348,460	'
Cash used in operations	'	'	$365,038	'	'	'